These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 23443310)
1. Pharmacokinetics of oseltamivir carboxylate in critically ill patients: each patient is unique. Kromdijk W; Sikma MA; van den Broek MP; Beijnen JH; Huitema AD; de Lange DW Intensive Care Med; 2013 May; 39(5):977-8. PubMed ID: 23443310 [No Abstract] [Full Text] [Related]
2. Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation. Eyler RF; Heung M; Pleva M; Sowinski KM; Park PK; Napolitano LM; Mueller BA Pharmacotherapy; 2012 Dec; 32(12):1061-9. PubMed ID: 23208833 [TBL] [Abstract][Full Text] [Related]
3. Impact of extracorporeal membrane oxygenation and continuous venovenous hemodiafiltration on the pharmacokinetics of oseltamivir carboxylate in critically ill patients with pandemic (H1N1) influenza. Lemaitre F; Luyt CE; Roullet-Renoleau F; Nieszkowska A; Zahr N; Corvol E; Fernandez C; Antignac M; Farinotti R; Combes A Ther Drug Monit; 2012 Apr; 34(2):171-5. PubMed ID: 22354159 [TBL] [Abstract][Full Text] [Related]
4. Oseltamivir carboxylate accumulation in a patient treated by haemodiafiltration and extracorporeal membrane oxygenation. Lemaitre F; Luyt CE; Roullet-Renoleau F; Nieszkowska A; Zahr N; Fernandez C; Farinotti R; Combes A Intensive Care Med; 2010 Jul; 36(7):1273-4. PubMed ID: 20376428 [No Abstract] [Full Text] [Related]
11. Safety and pharmacokinetics of oseltamivir for prophylaxis of neonates exposed to influenza H1N1. Maltezou HC; Drakoulis N; Siahanidou T; Karalis V; Zervaki E; Dotsikas Y; Loukas YL; Theodoridou M Pediatr Infect Dis J; 2012 May; 31(5):527-9. PubMed ID: 22209917 [TBL] [Abstract][Full Text] [Related]
12. Triple-combination antiviral drug for pandemic H1N1 influenza virus infection in critically ill patients on mechanical ventilation. Kim WY; Young Suh G; Huh JW; Kim SH; Kim MJ; Kim YS; Kim HR; Ryu YJ; Han MS; Ko YG; Chon GR; Lee KH; Choi SH; Hong SB; Antimicrob Agents Chemother; 2011 Dec; 55(12):5703-9. PubMed ID: 21968371 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic-pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studies. Rayner CR; Bulik CC; Kamal MA; Reynolds DK; Toovey S; Hammel JP; Smith PF; Bhavnani SM; Van Wart SA; Ambrose PG; Forrest A Antimicrob Agents Chemother; 2013 Aug; 57(8):3478-87. PubMed ID: 23669386 [TBL] [Abstract][Full Text] [Related]
14. Oseltamivir dosing in children undergoing hemodialysis. Schreuder MF; van der Flier M; Knops NB; Koster-Kamphuis L; Brüggemann RJ Clin Infect Dis; 2010 May; 50(10):1427-8. PubMed ID: 20397934 [No Abstract] [Full Text] [Related]
15. Comparison of anti-influenza virus activity and pharmacokinetics of oseltamivir free base and oseltamivir phosphate. Shin JS; Ku KB; Jang Y; Yoon YS; Shin D; Kwon OS; Go YY; Kim SS; Bae MA; Kim M J Microbiol; 2017 Dec; 55(12):979-983. PubMed ID: 29214495 [TBL] [Abstract][Full Text] [Related]
16. Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. Ariano RE; Sitar DS; Zelenitsky SA; Zarychanski R; Pisipati A; Ahern S; Kanji S; Rello J; Kumar A CMAJ; 2010 Mar; 182(4):357-63. PubMed ID: 20159892 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of the Monoclonal Antibody MHAA4549A Administered in Combination With Oseltamivir in Patients Hospitalized With Severe Influenza A Infection. Deng R; She G; Maia M; Lim JJ; Peck MC; McBride JM; Kulkarni P; Horn P; Castro A; Newton E; Tavel JA; Hanley WD J Clin Pharmacol; 2020 Nov; 60(11):1509-1518. PubMed ID: 32621543 [TBL] [Abstract][Full Text] [Related]
18. High levels and safety of oseltamivir carboxylate plasma concentrations after nasogastric administration in critically ill children in a pediatric intensive care unit. Giraud C; Manceau S; Oualha M; Chappuy H; Mogenet A; Duchêne P; Ducrocq S; Hubert P; Treluyer JM Antimicrob Agents Chemother; 2011 Jan; 55(1):433-5. PubMed ID: 20937783 [TBL] [Abstract][Full Text] [Related]
19. Carboxylesterase 1 polymorphism impairs oseltamivir bioactivation in humans. Tarkiainen EK; Backman JT; Neuvonen M; Neuvonen PJ; Schwab M; Niemi M Clin Pharmacol Ther; 2012 Jul; 92(1):68-71. PubMed ID: 22588607 [TBL] [Abstract][Full Text] [Related]
20. Failure of combination oral oseltamivir and inhaled zanamivir antiviral treatment in ventilator- and ECMO-treated critically ill patients with pandemic influenza A (H1N1)v. Petersen E; Keld DB; Ellermann-Eriksen S; Gubbels S; Ilkjær S; Jensen-Fangel S; Lindskov C Scand J Infect Dis; 2011 Jul; 43(6-7):495-503. PubMed ID: 21309638 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]